How is an ischemic stroke classified according to the involved vessel (large‑artery atherosclerosis, small‑vessel disease, cardioembolic, other determined, undetermined) and what are the recommended diagnostic work‑up and secondary‑prevention treatments for each category?

Stroke Vessel Categorization and Management

Ischemic stroke is classified into five major etiologic categories using the TOAST classification system: (1) large-artery atherosclerosis, (2) small-vessel occlusion (lacunar), (3) cardioembolism, (4) stroke of other determined etiology, and (5) stroke of undetermined etiology, with each requiring specific diagnostic workup and tailored secondary prevention strategies 1, 2.

Classification System Framework

The TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification remains the gold standard for stroke subtyping, demonstrating high interobserver agreement and practical clinical utility 2. The 2021 AHA/ASA guidelines formally adopted these definitions with specific imaging criteria 1:

The Five Major Categories

1. Large-Artery Atherosclerosis (≈17% of ischemic strokes)

• Definition: Ischemic stroke in the distribution of a major intracranial or extracranial artery with >50% stenosis or occlusion on vascular imaging 1
• Clinical findings include cortical or cerebellar lesions, or brainstem/subcortical hemispheric infarcts >1.5 cm 3, 2

2. Small-Vessel Disease/Lacunar (≈26% of ischemic strokes)

• Definition: Subcortical stroke measuring <1.5 cm in diameter on CT or MRI without evidence of concomitant cortical infarct 1
• Most lacunar strokes are due to small vessel disease, though not all 1

3. Cardioembolic Stroke (≈19-35% of ischemic strokes)

• Definition: Stroke attributable to arterial occlusion from an embolus arising in the heart 1
• Evidence of previous TIA or stroke in >1 vascular territory supports this diagnosis 1

4. Other Determined Etiology (≈1-3%)

• Includes rare causes such as arterial dissection, vasculitis, hypercoagulable states, and other specific mechanisms 2

5. Undetermined Etiology/Cryptogenic (≈9-29%)

• Cryptogenic stroke definition: Imaging-confirmed stroke with unknown source despite thorough diagnostic assessment 1
• May have two or more possible causes, negative evaluation, or incomplete workup 4, 2

Diagnostic Work-Up Algorithm

Minimum Required Evaluation (for all patients)

The 2021 AHA/ASA guidelines specify that cryptogenic stroke diagnosis requires at minimum 1:

1. Arterial imaging (MRA, CTA, or carotid ultrasound with transcranial Doppler)
2. Echocardiography (transthoracic initially)
3. Extended rhythm monitoring (not just admission ECG)
4. Key laboratory studies: Lipid profile and HbA1c

Subtype-Specific Diagnostic Pathways

For Suspected Large-Artery Atherosclerosis:

• CT angiography or MR angiography of head and neck to identify stenosis ≥50% 3
• Carotid ultrasound with plaque characterization
• Critical pitfall: Non-stenosing plaques (<50% stenosis) can cause embolic stroke through superimposed thrombus formation but may be misclassified as cryptogenic 5

For Suspected Cardioembolic Source:

• Transthoracic echocardiography as first-line
• Transoesophageal echocardiography (TEE) indicated when standard evaluation is negative, as it identifies embolic sources (aortic arch plaques >4mm, ulcerated plaques) in approximately 50% of patients with initially undetermined etiology 4
• Prolonged cardiac monitoring (≥24 hours, ideally 30 days) to detect paroxysmal atrial fibrillation

For Suspected Small-Vessel Disease:

• MRI with diffusion-weighted imaging to confirm lesion size <1.5 cm and subcortical location 1, 3
• Exclude cortical involvement
• Assess for vascular risk factors (hypertension, diabetes)

For Undetermined Etiology:

• Complete the minimum required evaluation above
• Consider TEE if transthoracic echo negative 4
• Extended cardiac monitoring (30-day event monitors or implantable loop recorders)
• Hypercoagulability workup in selected young patients or those with recurrent events

Secondary Prevention by Etiology

Large-Artery Atherosclerosis

Antiplatelet therapy:

• Single antiplatelet agent (aspirin, clopidogrel) for long-term prevention
• Consider dual antiplatelet therapy (DAPT) in acute phase, though the 2021 guidelines note ongoing evaluation of DAPT benefits versus risks within 5 years 1

Revascularization:

• Carotid endarterectomy or stenting for symptomatic stenosis ≥50% (especially ≥70%)
• Aggressive lipid management with high-intensity statins
• Blood pressure control, diabetes management

Critical consideration: Even small non-stenosing plaques can cause recurrent embolic events through thrombus formation, requiring anticoagulation until thrombus resolution, then possible stenting 5

Small-Vessel Disease

Primary strategy:

• Single antiplatelet agent (aspirin or clopidogrel)
• Aggressive blood pressure control (most critical intervention)
• Diabetes management with HbA1c monitoring
• Statin therapy

Cardioembolic Stroke

Anticoagulation is the cornerstone:

• Oral anticoagulation (warfarin or direct oral anticoagulants) for atrial fibrillation and most cardioembolic sources
• Timing of anticoagulation initiation depends on infarct size and hemorrhagic transformation risk
• Antiplatelet therapy is inferior to anticoagulation for cardioembolic sources 6

Atrial fibrillation management:

• Continuous monitoring to detect paroxysmal episodes
• Risk stratification using CHA₂DS₂-VASc score
• DOACs preferred over warfarin in most patients

Other Determined Etiology

Treatment is mechanism-specific:

• Arterial dissection: antiplatelet or anticoagulation (controversial, individualized)
• Hypercoagulable states: anticoagulation
• Vasculitis: immunosuppression plus antithrombotic therapy

Undetermined/Cryptogenic Stroke

Management approach:

• If truly cryptogenic after complete evaluation: antiplatelet therapy is standard 1
• Ongoing investigation into anticoagulation for embolic stroke of undetermined source (ESUS), though current evidence does not support routine anticoagulation over antiplatelet therapy
• Recurrence risk consideration: Cardioembolism is more common at recurrence (18% vs 10.7% at first event), suggesting occult cardiac sources may declare themselves over time 7

Critical Pitfalls to Avoid

1. Incomplete evaluation leading to misclassification: Studies show 29-30% of strokes remain undetermined, but approximately half can be reclassified with TEE 4. Don't accept "cryptogenic" without completing minimum diagnostic criteria.

2. Overlooking non-stenosing plaques: Plaques causing <50% stenosis can still cause embolic stroke through superimposed thrombus and may cause multiple recurrent events if not identified 5.

3. Inadequate cardiac monitoring: Single admission ECG misses paroxysmal atrial fibrillation. Extended monitoring (30 days minimum) is essential 1.

4. Assuming lacunar = small vessel disease: While most lacunar strokes are due to small vessel disease, not all are. Consider alternative etiologies if risk factors don't fit 1.

5. Using antiplatelet therapy for cardioembolic stroke: This is inferior to anticoagulation and increases recurrence risk 6.

Practical Implementation

The diagnostic pattern on diffusion-weighted MRI combined with MR angiography vessel involvement patterns can suggest the most likely causative mechanism and guide additional testing 3. This multimodal imaging approach in the acute phase improves diagnostic accuracy and should be obtained early when feasible.

Approximately 70% of patients can receive definitive etiologic diagnosis with standard emergency department evaluation (clinical assessment, CT/MRI, ECG, carotid ultrasound, transthoracic echo) 4. The remaining 30% require extended workup, particularly TEE and prolonged cardiac monitoring.